Janus kinase inhibitors in myeloproliferative neoplasms: Clinical applications

Australian Prescriber

Volumn 37, Issue 5, 2014, Pages 161-162

  Bazargan, Ali ^a   Tam, Constantine ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Essential thrombocythaemia; Molecular targeted therapy; Myelofibrosis; Polycythaemia vera; Ruxolitinib

Indexed keywords

JANUS KINASE 2 INHIBITOR; MOMELOTINIB; PACRITINIB; PLACEBO; RUXOLITINIB;

ANEMIA; ARTICLE; BONE PAIN; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DIZZINESS; DRUG EFFICACY; GENE; GENE MUTATION; HEADACHE; HEMATOCRIT; HUMAN; JANUS KINASE 2 GENE; MOLECULARLY TARGETED THERAPY; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NIGHT SWEAT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; PRURITUS; QUALITY OF LIFE; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84929922823     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2014.063     Document Type: Article

References (11)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
5. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17.
6. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
7. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98.
8. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I [abstract]. 54th ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA.
9. Cervantes F, Kiladjian JJ, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuity M, et al. Long-term safety, efficacy, and survival findings from COMFORT-II, a Phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) [abstract]. 54th ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA.
10. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, He S, et al. Long-term efficacy and safety results from a Phase II study of ruxolitinib in patients with polycythemia vera [abstract]. ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA.
11. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Levy RA, et al. Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU) [abstract]. ASH Annual Meeting and Exposition; 2011 Dec 10-13; Valencia, BC.